What is the latest KREBSBIO stock price?
The latest stored price for KREBSBIO is Rs 57.31 as of 2026-09-18.
gimli
KREBSBIO stock AI analysis
KREBSBIO Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
KREBS BIOCHEMICALS & IND is a small-cap stock in Healthcare. This Gimli page shows the latest available KREBSBIO price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹57.31
1W return
-6.77%
1M return
+2.72%
3M return
-10.88%
6M return
+18.16%
1Y return
-27.20%
Market cap
₹123.56 cr
PE
-8.77
PB
-0.76
ROE
+9.12%
ROCE
-9.64%
RSI
52.68
Turnover
₹0.31 cr
Why it can matter in screens
- Momentum: KREBSBIO is above 50DMA, below 200DMA; RSI is 52.68.
- Returns: 1D +3.30%, 1W -6.77%, 1M +2.72%, 3M -10.88%, 1Y -27.20%.
- Trend levels: 52W high ₹71.50, 52W low ₹50.81, off high -19.85%.
- Liquidity: latest turnover is ₹0.31 cr; volume vs 20D is +2.98%.
- Valuation/profitability: PE -8.77, PB -0.76, ROE +9.12%, ROCE -9.64%.
- Growth: 3Y sales CAGR -23.07%, 3Y profit CAGR n/a.
Quick Answers
Is KREBSBIO above its 50DMA and 200DMA?
KREBSBIO is above 50DMA, below 200DMA. The latest 50DMA is 55.19 and the latest 200DMA is 59.36.
What are KREBSBIO PE, ROE and ROCE?
KREBSBIO has PE -8.77, ROE +9.12%, and ROCE -9.64% in Gimli's latest available snapshot.
How has KREBSBIO performed recently?
KREBSBIO has returned +2.72% over 1 month, -10.88% over 3 months, and -27.20% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 7.14 cr | 0.99 cr | -2.48 cr | -1.15 |
| 2026-03-31 | 6.81 cr | 1.14 cr | -2.34 cr | -1.09 |
| 2025-12-31 | 7.27 cr | 0.30 cr | -3.13 cr | -1.45 |
| 2025-09-30 | 4.17 cr | -2.79 cr | -6.14 cr | -2.85 |
| 2025-06-30 | 5.48 cr | -2.08 cr | -5.32 cr | -2.47 |
| 2025-03-31 | 6.10 cr | -5.07 cr | -8.27 cr | -3.83 |
| 2024-12-31 | 11.47 cr | -4.46 cr | -7.74 cr | -3.59 |
| 2024-09-30 | 12.86 cr | -2.62 cr | n/a | -2.67 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 23.73 cr | -3.42 cr | -16.93 cr | nan |
| 2025-03-31 | 43.31 cr | -14.32 cr | -26.94 cr | -12.49 |
| 2024-03-31 | 50.42 cr | -8.28 cr | -19.73 cr | -9.15 |
| 2023-03-31 | 52.13 cr | -15.16 cr | -24.69 cr | -11.30 |
| 2022-03-31 | 60.86 cr | -32.85 cr | -44.53 cr | -20.81 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 163.25 cr | 0.13 cr | 224.84 cr | -162.75 cr |
| 2025-03-31 | 169.04 cr | 0.14 cr | 212.21 cr | -146.24 cr |
| 2024-03-31 | 178.17 cr | 0.07 cr | 238.68 cr | -119.22 cr |
| 2023-03-31 | 174.98 cr | 0.02 cr | 228.37 cr | -99.46 cr |
| 2022-03-31 | 189.81 cr | 0.03 cr | 188.10 cr | -75.09 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | -1.92 cr | -5.09 cr | n/a |
| 2025-03-31 | -7.89 cr | -11.45 cr | n/a |
| 2024-03-31 | 2.36 cr | -7.05 cr | n/a |
| 2023-03-31 | -24.71 cr | -35.58 cr | n/a |
| 2022-03-31 | -17.22 cr | -40.74 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +72.74% | +0.50% | +0.00% | +0.00% | +26.76% | +0.00% |
| 2026-03-31 | +72.74% | +0.50% | +0.00% | +0.00% | +26.76% | +0.00% |
| 2025-12-31 | +72.74% | +0.50% | +0.00% | +0.00% | +26.76% | +0.00% |
| 2025-09-30 | +72.74% | +0.50% | +0.00% | +0.00% | +26.76% | +0.00% |
| 2025-06-30 | +72.74% | +0.50% | +0.00% | +0.00% | +26.76% | +0.00% |
| 2025-03-31 | +72.74% | +0.50% | +0.00% | +0.00% | +26.76% | +0.00% |
| 2024-12-31 | +72.74% | +0.50% | +0.00% | +0.00% | +26.76% | +0.00% |
| 2024-09-30 | +72.74% | +0.50% | +0.00% | +0.00% | +26.76% | +0.00% |
| 2024-06-30 | +72.74% | +0.50% | +0.00% | +0.00% | +26.76% | +0.00% |
| 2024-03-31 | +72.74% | +0.50% | +0.00% | +0.00% | +26.76% | +0.00% |
| 2023-12-31 | +72.74% | +0.50% | +0.00% | +0.00% | +26.77% | n/a |
| 2023-09-30 | +72.74% | +0.50% | +0.00% | +0.00% | +26.76% | n/a |
| 2023-06-30 | +72.74% | +0.50% | +0.00% | +0.00% | +26.76% | +0.00% |
| 2023-03-31 | +72.74% | +0.50% | +0.00% | +0.00% | +26.76% | +0.00% |
| 2022-12-31 | +72.74% | +0.33% | +0.00% | +0.00% | +26.93% | +0.00% |
| 2022-09-30 | +72.74% | +0.01% | +0.00% | +0.00% | +27.25% | +0.00% |
| 2022-06-30 | +72.74% | +0.00% | +0.01% | n/a | n/a | +0.00% |
| 2022-03-31 | +72.74% | +0.00% | +0.01% | n/a | n/a | n/a |
| 2021-12-31 | +72.74% | +0.00% | +0.01% | n/a | n/a | +0.00% |
| 2021-09-30 | +72.74% | +0.00% | +0.01% | n/a | n/a | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 440,829.82 cr | 36.388220 | +15.50% | +11.45% |
| DIVISLAB | DIVI S LABORATORIES LTD | 248,876.81 cr | 85.407280 | +18.37% | +53.39% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 163,807.57 cr | 75.106636 | +17.33% | +35.67% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 128,608.22 cr | 65.670049 | +21.03% | +13.94% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 116,723.14 cr | 26.011308 | +16.04% | +10.70% |
| CIPLA | CIPLA LTD | 112,647.78 cr | 33.401961 | +10.25% | -11.64% |
| LAURUSLABS | LAURUS LABS LIMITED | 105,487.98 cr | 96.587446 | +21.77% | +111.64% |
| MAXHEALTH | MAX HEALTHCARE INS LTD | 102,122.47 cr | 70.799892 | +14.33% | -10.58% |
Try these prompts
- Analyze KREBS BIOCHEMICALS & IND with valuation, momentum and industry peers
- Compare KREBSBIO with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare KREBSBIO with other Healthcare stocks
Data snapshot: 2026-09-18. Not investment advice.